Now Reading: Thermo Fisher plans bigger India investments as biologics demand rises
-
01
Thermo Fisher plans bigger India investments as biologics demand rises
Thermo Fisher plans bigger India investments as biologics demand rises
Thermo Fisher Scientific is stepping up investments in India as drugmakers increase work on innovative medicines and biosimilars, The Economic Times reports. The US-based laboratory equipment maker said India recorded its fastest…
The Story in Brief
Thermo Fisher Scientific is stepping up investments in India as drugmakers increase work on innovative medicines and biosimilars, The Economic Times reports. The US-based laboratory equipment maker said India recorded its fastest growth in the Asia-Pacific and Middle East region over the past year. It expects double-digit returns from the market over the next five years, though it did not disclose India revenue or planned investment amounts.
Demand is growing for bioprocessing equipment, laboratory analysers, automation systems and protein-characterisation technologies. A BCG report projects India’s biosimilars exports will rise from $800 million to $4.2 billion by 2030, with the US as a key target. Thermo Fisher opened a bioprocess design and customer experience centre in Hyderabad last year.
The Indian Opinion
The easy story is that India’s biologics opportunity will automatically deliver export gains. The opposite claim, that foreign equipment firms are merely selling into a crowded market, is also incomplete. Thermo Fisher has identified demand, but it has not disclosed investment figures or India revenue. The useful test is whether Indian drugmakers convert new capacity and training into approved products and exports, with the $4.2 billion projection providing a clear benchmark by 2030.
Source: health.economictimes.indiatimes.com
This story was synthesised by AI from the source linked above.
